What’s the current market cap for SIGA Technologies stock?

SIGA Technologies (SIGA) has a market cap of $341M as of May 29, 2026.

What is the P/E ratio for SIGA Technologies stock?

The price to earnings (P/E) ratio for SIGA Technologies (SIGA) stock is 17.01 as of May 29, 2026.

Does SIGA Technologies stock pay dividends?

Yes, the SIGA Technologies (SIGA) stock pays dividends to shareholders. As of May 29, 2026, the dividend rate is $0.6 and the yield is 12.61%. SIGA Technologies has a payout ratio of 0.79% on a trailing twelve-month basis.

When is the next SIGA Technologies dividend payment date?

The next SIGA Technologies (SIGA) dividend payment date is unconfirmed.

What is the beta indicator for SIGA Technologies?

SIGA Technologies (SIGA) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy SIGA Technologies stock | $SIGA Share Price

13:30

15:10

16:45

18:25

20:00

About SIGA Technologies

SIGA Technologies Inc a commercial-stage pharmaceutical company. The Company sells its product, TPOX oral TPOXX, also known as tecovirimat, Tecovirimat-SIGA, or TEPOXX (tecovirimat) in certain international markets, to the U.S. Government and international governments (including government-affiliated entities). The Company operates in one single operating and reportable segment, which includes all activities related to the sale of the Company's Oral and IV TPOXX as well as research and development services.

Ticker

$SIGA

Sector

Health

Primary listing

NASDAQ

Employees

Headquarters

New York, United States

Website

www.siga.com

SIGA Metrics

BasicAdvanced

$341m

17.01

$0.28

0.85

$0.60

12.61%

What the Analysts think about SIGA

Analyst ratings (Buy, Hold, Sell) for SIGA Technologies stock.

Bulls say / Bears say

Secured over $1 billion in procurement contracts with governments globally, confirming a strong contract pipeline and steady government demand (itiger.com)

Generated about $680 million in product revenue and $395 million in pre-tax operating income from 2020 to 2025, demonstrating profitable operations with attractive margins (itiger.com)

Sold TPOXX in more than 30 countries, showing extensive global market penetration and broad international acceptance (itiger.com)

Revenue is volatile from quarter to quarter because government procurement is irregular, leading to inconsistent sales and making short-term forecasts difficult (s204.q4cdn.com)

The critical 19C BARDA contract is nearing expiration without a confirmed replacement, creating a risk of revenue disruption if the U.S. government delays a new award (s204.q4cdn.com)

A pending EMA referral could result in the withdrawal of the mpox indication, reducing Tecovirimat’s regulatory approvals and limiting market potential in Europe (s204.q4cdn.com)

Data summarised monthly by Lightyear AI. Last updated on 22 May 2026.

SIGA Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

SIGA Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SIGA

Capital at risk

Market open

Upcoming events

No upcoming events